<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20230822203524&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20230822203524&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Wed, 23 Aug 2023 00:35:26 +0000</lastbuilddate>
<pubDate>Tue, 22 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Antithrombotic treatment: personalized antiplatelet therapies and lessons from the gut microbiota</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37607038/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 22;44(32):3023-3026. doi: 10.1093/eurheartj/ehad521.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37607038/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37607038</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad521>10.1093/eurheartj/ehad521</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37607038</guid>
<pubDate>Tue, 22 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-08-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Antithrombotic treatment: personalized antiplatelet therapies and lessons from the gut microbiota</dc:title>
<dc:identifier>pmid:37607038</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad521</dc:identifier>
</item>
<item>
<title>Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37606064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>Patient-reported outcomes (PROs) provide important insights into patients' own perspectives about their health and medical condition, and there is evidence that their use can lead to improvements in the quality of care and to better-informed clinical decisions. Their application in cardiovascular populations has grown over the past decades. This statement describes what PROs are, and it provides an inventory of disease-specific and domain-specific PROs that have been developed for cardiovascular...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 22:ehad514. doi: 10.1093/eurheartj/ehad514. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Patient-reported outcomes (PROs) provide important insights into patients' own perspectives about their health and medical condition, and there is evidence that their use can lead to improvements in the quality of care and to better-informed clinical decisions. Their application in cardiovascular populations has grown over the past decades. This statement describes what PROs are, and it provides an inventory of disease-specific and domain-specific PROs that have been developed for cardiovascular populations. International standards and quality indices have been published, which can guide the selection of PROs for clinical practice and in clinical trials and research; patients as well as experts in psychometrics should be involved in choosing which are most appropriate. Collaborations are needed to define criteria for using PROs to guide regulatory decisions, and the utility of PROs for comparing and monitoring the quality of care and for allocating resources should be evaluated. New sources for recording PROs include wearable digital health devices, medical registries, and electronic health record. Advice is given for the optimal use of PROs in shared clinical decision-making in cardiovascular medicine, and concerning future directions for their wider application.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37606064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37606064</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad514>10.1093/eurheartj/ehad514</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37606064</guid>
<pubDate>Tue, 22 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Philip Moons</dc:creator>
<dc:creator>Tone M Norekvål</dc:creator>
<dc:creator>Elena Arbelo</dc:creator>
<dc:creator>Britt Borregaard</dc:creator>
<dc:creator>Barbara Casadei</dc:creator>
<dc:creator>Bernard Cosyns</dc:creator>
<dc:creator>Martin R Cowie</dc:creator>
<dc:creator>Donna Fitzsimons</dc:creator>
<dc:creator>Alan G Fraser</dc:creator>
<dc:creator>Tiny Jaarsma</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:creator>Josepa Mauri</dc:creator>
<dc:creator>Richard Mindham</dc:creator>
<dc:creator>Julie Sanders</dc:creator>
<dc:creator>Francois Schiele</dc:creator>
<dc:creator>Aleksandra Torbica</dc:creator>
<dc:creator>Ann Dorthe Zwisler</dc:creator>
<dc:date>2023-08-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management</dc:title>
<dc:identifier>pmid:37606064</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad514</dc:identifier>
</item>
<item>
<title>Brain α2δ-1-Bound NMDA Receptors Drive Calcineurin Inhibitor-Induced Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37605933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These findings indicate that α2δ-1 is essential for calcineurin inhibitor-induced increases in synaptic NMDAR activity in PVN presympathetic neurons and sympathetic outflow. Thus, α2δ-1 and α2δ-1-bound NMDARs represent new targets for treating calcineurin inhibitor-induced hypertension.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 22. doi: 10.1161/CIRCRESAHA.123.322562. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Calcineurin is highly enriched in immune T cells and in the nervous system. Calcineurin inhibitors, including cyclosporine and tacrolimus (FK506), are the cornerstone of immunosuppressive regimens for preserving transplanted organs and tissues. However, these drugs often cause persistent hypertension owing to excess sympathetic outflow, which is maintained by N-methyl-D-aspartate receptor (NMDAR)-mediated excitatory input to the hypothalamic paraventricular nucleus (PVN). It is unclear how calcineurin inhibitors increase NMDAR activity in the PVN to augment sympathetic vasomotor activity. α2δ-1 (encoded by the <i>Cacna2d1</i> gene), known colloquially as a calcium channel subunit, is a newly discovered NMDAR-interacting protein. Here, we determined whether α2δ-1 plays a role in calcineurin inhibitor-induced synaptic NMDAR hyperactivity in the PVN and hypertension development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Immunoblotting and coimmunoprecipitation assays revealed that prolonged treatment with FK506 in rats significantly increased protein levels of α2δ-1, GluN1 (the obligatory NMDAR subunit), and the α2δ-1-GluN1 complex in PVN synaptosomes. These effects were blocked by inhibiting α2δ-1 with gabapentin or interrupting the α2δ-1-NMDAR interaction with an α2δ-1 C-terminus peptide. Whole-cell recordings in brain slices showed that treatment with FK506 potentiated the activity of presynaptic and postsynaptic NMDARs in spinally projecting PVN neurons; such effects were abolished by gabapentin, <i>Cacna2d1</i> knockout, or α2δ-1 C-terminus peptide. Furthermore, microinjection of α2δ-1 C-terminus peptide into the PVN diminished renal sympathetic nerve discharges and arterial blood pressure that had been increased by FK506 treatment. Remarkably, telemetry recording showed that concurrent administration of gabapentin prevented the development of FK506-induced hypertension in rats. Additionally, FK506 treatment induced sustained hypertension in wild-type mice but not in <i>Cacna2d1</i> knockout mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings indicate that α2δ-1 is essential for calcineurin inhibitor-induced increases in synaptic NMDAR activity in PVN presympathetic neurons and sympathetic outflow. Thus, α2δ-1 and α2δ-1-bound NMDARs represent new targets for treating calcineurin inhibitor-induced hypertension.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37605933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37605933</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322562>10.1161/CIRCRESAHA.123.322562</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37605933</guid>
<pubDate>Tue, 22 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jing-Jing Zhou</dc:creator>
<dc:creator>Jian-Ying Shao</dc:creator>
<dc:creator>Shao-Rui Chen</dc:creator>
<dc:creator>Hui-Lin Pan</dc:creator>
<dc:date>2023-08-22</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Brain α2δ-1-Bound NMDA Receptors Drive Calcineurin Inhibitor-Induced Hypertension</dc:title>
<dc:identifier>pmid:37605933</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322562</dc:identifier>
</item>
<item>
<title>Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37605637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: MRAs did not influence SGLT2i effects on the composite of HHF/CVD, HHF or all-cause mortality; however, findings hinted at a more pronounced relative reduction in CVD in chronic HF patients regardless of EF who were randomized to SGLT2i and receiving an MRA compared to those randomized to SGLT2i and not receiving MRAs. SGLT2i attenuated the risk of MRA-associated treatment-emergent hyperkalaemia. These findings warrant further validation in well-designed randomized controlled...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 22:ehad522. doi: 10.1093/eurheartj/ehad522. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: To investigate the cardiovascular effects of sodium-glucose co-transporter-2 inhibitors (SGLT2i) with concomitant mineralocorticoid receptor antagonist (MRA) use in heart failure (HF) regardless of ejection fraction (EF) and explore the risk of MRA-associated adverse events in individuals randomized to SGLT2i vs. placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PubMed/MEDLINE, Web of Science, Embase, and clinical trial registries were searched for randomized controlled trials/post-hoc analyses evaluating SGLT2i in HF with or without MRA use (PROSPERO: CRD42023397129). The main outcomes were composite of first hospitalization or urgent visit for HF/cardiovascular death (HHF/CVD), HHF, and CVD. Others were all-cause mortality, composite renal and safety outcomes. Hazard ratios (HR)/risk ratios were extracted. Fixed-effects meta-analyses and subgroup analyses were performed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Five eligible studies were included, pooling data from 21 947 people with HF (type 2 diabetes mellitus, n = 10 805). Compared to placebo, randomization to SGLT2i showed a similar reduction in HHF/CVD and HHF in people who were or were not using MRAs [HHF/CVD: hazard ratio (HR) 0.75; 95% confidence interval (CI) 0.68-0.81 vs. HR 0.79; 95% CI 0.72-0.86; P-interaction = .43; HHF: HR 0.74; 95% CI 0.67-0.83 vs. HR 0.71; 95% CI 0.63-0.80; P-interaction = .53], with a suggestion of greater relative reduction in CVD in chronic HF people randomized to SGLT2i and using MRAs irrespective of EF (HR 0.81; 95% CI 0.72-0.91 vs. HR 0.98; 95% CI 0.86-1.13; P-interaction = .034). SGLT2i reduced all-cause mortality (P-interaction = .27) and adverse renal endpoints regardless of MRA use (P-interaction = .73) despite a higher risk of volume depletion with concomitant MRAs (P-interaction = .082). SGLT2i attenuated the risk of mild hyperkalaemia (P-interaction &lt; .001) and severe hyperkalaemia (P-interaction = .051) associated with MRA use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: MRAs did not influence SGLT2i effects on the composite of HHF/CVD, HHF or all-cause mortality; however, findings hinted at a more pronounced relative reduction in CVD in chronic HF patients regardless of EF who were randomized to SGLT2i and receiving an MRA compared to those randomized to SGLT2i and not receiving MRAs. SGLT2i attenuated the risk of MRA-associated treatment-emergent hyperkalaemia. These findings warrant further validation in well-designed randomized controlled trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37605637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37605637</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad522>10.1093/eurheartj/ehad522</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37605637</guid>
<pubDate>Tue, 22 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mainak Banerjee</dc:creator>
<dc:creator>Indira Maisnam</dc:creator>
<dc:creator>Rimesh Pal</dc:creator>
<dc:creator>Satinath Mukhopadhyay</dc:creator>
<dc:date>2023-08-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis</dc:title>
<dc:identifier>pmid:37605637</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad522</dc:identifier>
</item>
<item>
<title>Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37603606/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 22;148(8):e8. doi: 10.1161/CIR.0000000000001177. Epub 2023 Aug 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37603606/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37603606</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001177>10.1161/CIR.0000000000001177</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37603606</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:37603606</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001177</dc:identifier>
</item>
<item>
<title>Bicuspid Aortic Valve and Thoracic Aortic Disease: Further Evidence of Clinically Silent but Deadly Risk to Family Members of Affected Individuals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37603605/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 22;148(8):648-650. doi: 10.1161/CIRCULATIONAHA.123.065406. Epub 2023 Aug 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37603605/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37603605</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065406>10.1161/CIRCULATIONAHA.123.065406</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37603605</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Siddharth K Prakash</dc:creator>
<dc:creator>Hector I Michelena</dc:creator>
<dc:creator>Dianna M Milewicz</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Bicuspid Aortic Valve and Thoracic Aortic Disease: Further Evidence of Clinically Silent but Deadly Risk to Family Members of Affected Individuals</dc:title>
<dc:identifier>pmid:37603605</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065406</dc:identifier>
</item>
<item>
<title>Selection and Interpretation of Molecular Diagnostics in Heart Transplantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37603604/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>The number of heart transplants performed annually in the United States and worldwide continues to increase, but there has been little change in graft longevity and patient survival over the past 2 decades. The reference standard for diagnosis of acute cellular and antibody-mediated rejection includes histologic and immunofluorescence evaluation of endomyocardial biopsy samples, despite invasiveness and high interrater variability for grading histologic rejection. Circulating biomarkers and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 22;148(8):679-694. doi: 10.1161/CIRCULATIONAHA.123.062847. Epub 2023 Aug 21.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The number of heart transplants performed annually in the United States and worldwide continues to increase, but there has been little change in graft longevity and patient survival over the past 2 decades. The reference standard for diagnosis of acute cellular and antibody-mediated rejection includes histologic and immunofluorescence evaluation of endomyocardial biopsy samples, despite invasiveness and high interrater variability for grading histologic rejection. Circulating biomarkers and molecular diagnostics have shown substantial predictive value in rejection monitoring, and emerging data support their use in diagnosing other posttransplant complications. The use of genomic (cell-free DNA), transcriptomic (mRNA and microRNA profiling), and proteomic (protein expression quantitation) methodologies in diagnosis of these posttransplant outcomes has been evaluated with varying levels of evidence. In parallel, growing knowledge about the genetically mediated immune response leading to rejection (immunogenetics) has enhanced understanding of antibody-mediated rejection, associated graft dysfunction, and death. Antibodies to donor human leukocyte antigens and the technology available to evaluate these antibodies continues to evolve. This review aims to provide an overview of biomarker and immunologic tests used to diagnose posttransplant complications. This includes a discussion of pediatric heart transplantation and the disparate rates of rejection and death experienced by Black patients receiving a heart transplant. This review describes diagnostic modalities that are available and used after transplant and the landscape of future investigations needed to enhance patient outcomes after heart transplantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37603604/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37603604</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.062847>10.1161/CIRCULATIONAHA.123.062847</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37603604</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jason F Goldberg</dc:creator>
<dc:creator>Lauren K Truby</dc:creator>
<dc:creator>Sean Agbor-Enoh</dc:creator>
<dc:creator>Annette M Jackson</dc:creator>
<dc:creator>Christopher R deFilippi</dc:creator>
<dc:creator>Kiran K Khush</dc:creator>
<dc:creator>Palak Shah</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Selection and Interpretation of Molecular Diagnostics in Heart Transplantation</dc:title>
<dc:identifier>pmid:37603604</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.062847</dc:identifier>
</item>
<item>
<title>Ethanol-Induced Atrial Fibrillation Results From Late &lt;em>;I&lt;/em>;&lt;sub>;Na&lt;/sub>; and Can Be Prevented by Ranolazine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37603603/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 22;148(8):698-700. doi: 10.1161/CIRCULATIONAHA.123.064561. Epub 2023 Aug 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37603603/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37603603</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064561>10.1161/CIRCULATIONAHA.123.064561</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37603603</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Julian Mustroph</dc:creator>
<dc:creator>Maria J Baier</dc:creator>
<dc:creator>Denise Unsin</dc:creator>
<dc:creator>Zdenek Provaznik</dc:creator>
<dc:creator>Kostiantyn Kozakov</dc:creator>
<dc:creator>Simon Lebek</dc:creator>
<dc:creator>Daniel Tarnowski</dc:creator>
<dc:creator>Sönke Schildt</dc:creator>
<dc:creator>Niels Voigt</dc:creator>
<dc:creator>Stefan Wagner</dc:creator>
<dc:creator>Lars S Maier</dc:creator>
<dc:creator>Stefan Neef</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ethanol-Induced Atrial Fibrillation Results From Late &lt;em>;I&lt;/em>;&lt;sub>;Na&lt;/sub>; and Can Be Prevented by Ranolazine</dc:title>
<dc:identifier>pmid:37603603</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064561</dc:identifier>
</item>
<item>
<title>Letter by Teng et al Regarding Article, "Gut Microbiota-Derived Trimethylamine N-Oxide Contributes to Abdominal Aortic Aneurysm Through Inflammatory and Apoptotic Mechanisms"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37603602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 22;148(8):701-702. doi: 10.1161/CIRCULATIONAHA.123.065557. Epub 2023 Aug 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37603602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37603602</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065557>10.1161/CIRCULATIONAHA.123.065557</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37603602</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Zhenqing Teng</dc:creator>
<dc:creator>Xiang Ma</dc:creator>
<dc:creator>Yitong Ma</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Teng et al Regarding Article, "Gut Microbiota-Derived Trimethylamine N-Oxide Contributes to Abdominal Aortic Aneurysm Through Inflammatory and Apoptotic Mechanisms"</dc:title>
<dc:identifier>pmid:37603602</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065557</dc:identifier>
</item>
<item>
<title>Micturition Syncope…Not Always Benign</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37603601/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 22;148(8):695-697. doi: 10.1161/CIRCULATIONAHA.123.066038. Epub 2023 Aug 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37603601/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37603601</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066038>10.1161/CIRCULATIONAHA.123.066038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37603601</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Munim Ali Khan</dc:creator>
<dc:creator>Sami Viskin</dc:creator>
<dc:creator>Christopher Madias</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Micturition Syncope…Not Always Benign</dc:title>
<dc:identifier>pmid:37603601</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066038</dc:identifier>
</item>
<item>
<title>Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37603600/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Multiple cardiorenal stress biomarkers are strongly prognostic in people with type 2 diabetes and albuminuria. Canagliflozin modestly reduced the longitudinal trajectory of rise in each biomarker. Change in the biomarker level in addition to the baseline level augments the primary outcome prediction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 22;148(8):651-660. doi: 10.1161/CIRCULATIONAHA.123.065251. Epub 2023 Aug 21.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: People with type 2 diabetes and albuminuria are at an elevated risk for cardiac and renal events. The optimal biomarkers to aid disease prediction and to understand the benefits of sodium-glucose cotransporter-2 inhibition remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among 2627 study participants in the CREDENCE trial (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), concentrations of NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity cardiac troponin T, growth differentiation factor-15, and IGFBP7 (insulin-like growth factor binding protein 7) were measured. The effect of canagliflozin on biomarker concentrations was evaluated. The prognostic potential of each biomarker on the primary outcome (a composite of end-stage kidney disease [dialysis, transplantation, or a sustained estimated glomerular filtration rate of &lt;15 mL·min<sup>-1</sup>·1.73 m<sup>-2</sup>], doubling of the serum creatinine level, or renal death or cardiovascular death) was assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The median (quartiles 1 and 3) concentration of each biomarker was generally elevated: NT-proBNP, 180 ng/L (82, 442 ng/L); high-sensitivity cardiac troponin T, 19 ng/L (12, 29 ng/L); growth differentiation factor-15, 2595 ng/L (1852, 3775 ng/L); and IGFBP7, 121.8 ng/mL (105.4, 141.5 ng/mL). At 1 year, the biomarkers all rose by 6% to 29% in the placebo arm but only by 3% to 10% in the canagliflozin arm (all <i>P</i>&lt;0.01 in multivariable linear mixed-effect models). Baseline concentrations of each biomarker were strongly predictive of cardiac and renal outcomes. When the biomarkers were analyzed together in a multimarker panel, individuals with high risk scores (hazard ratio [HR], 4.01 [95% CI, 2.52-6.35]) and moderate risk scores (HR, 2.39 [95% CI, 1.48-3.87]) showed a higher risk for the primary outcome compared with those with low risk scores. By 1 year, a 50% increase in NT-proBNP (HR, 1.11 [95% CI, 1.08-1.15]), high-sensitivity cardiac troponin T (HR, 1.86 [95% CI, 1.64-2.10]), growth differentiation factor-15 (HR, 1.45 [95% CI, 1.24-1.70]), and IGFBP7 (HR, 3.76 [95% CI, 2.54-5.56]) was associated with risk of the primary outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Multiple cardiorenal stress biomarkers are strongly prognostic in people with type 2 diabetes and albuminuria. Canagliflozin modestly reduced the longitudinal trajectory of rise in each biomarker. Change in the biomarker level in addition to the baseline level augments the primary outcome prediction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT02065791.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37603600/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37603600</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065251>10.1161/CIRCULATIONAHA.123.065251</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37603600</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Reza Mohebi</dc:creator>
<dc:creator>Yuxi Liu</dc:creator>
<dc:creator>Naveed Sattar</dc:creator>
<dc:creator>Hiddo J L Heerspink</dc:creator>
<dc:creator>Eshetu Tefera</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Yshai Yavin</dc:creator>
<dc:creator>Jingwei Li</dc:creator>
<dc:creator>Carol A Pollock</dc:creator>
<dc:creator>Vlado Perkovic</dc:creator>
<dc:creator>Bruce Neal</dc:creator>
<dc:creator>Michael K Hansen</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial</dc:title>
<dc:identifier>pmid:37603600</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065251</dc:identifier>
</item>
<item>
<title>Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37602409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Collectively, these results advance the application of cardiac reprogramming gene therapy as a viable therapeutic approach to treat chronic heart failure resulting from ischemic injury.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 21. doi: 10.1161/CIRCULATIONAHA.122.061542. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac reprogramming is a technique to directly convert nonmyocytes into myocardial cells using genes or small molecules. This intervention provides functional benefit to the rodent heart when delivered at the time of myocardial infarction or activated transgenically up to 4 weeks after myocardial infarction. Yet, several hurdles have prevented the advancement of cardiac reprogramming for clinical use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Through a combination of screening and rational design, we identified a cardiac reprogramming cocktail that can be encoded in a single adeno-associated virus. We also created a novel adeno-associated virus capsid that can transduce cardiac fibroblasts more efficiently than available parental serotypes by mutating posttranslationally modified capsid residues. Because a constitutive promoter was needed to drive high expression of these cell fate-altering reprogramming factors, we included binding sites to a cardiomyocyte-restricted microRNA within the 3' untranslated region of the expression cassette that limits expression to nonmyocytes. After optimizing this expression cassette to reprogram human cardiac fibroblasts into induced cardiomyocyte-like cells in vitro, we also tested the ability of this capsid/cassette combination to confer functional benefit in acute mouse myocardial infarction and chronic rat myocardial infarction models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We demonstrated sustained, dose-dependent improvement in cardiac function when treating a rat model 2 weeks after myocardial infarction, showing that cardiac reprogramming, when delivered in a single, clinically relevant adeno-associated virus vector, can support functional improvement in the postremodeled heart. This benefit was not observed with GFP (green fluorescent protein) or a hepatocyte reprogramming cocktail and was achieved even in the presence of immunosuppression, supporting myocyte formation as the underlying mechanism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Collectively, these results advance the application of cardiac reprogramming gene therapy as a viable therapeutic approach to treat chronic heart failure resulting from ischemic injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37602409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37602409</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061542>10.1161/CIRCULATIONAHA.122.061542</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37602409</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Huanyu Zhou</dc:creator>
<dc:creator>Jin Yang</dc:creator>
<dc:creator>Chetan Srinath</dc:creator>
<dc:creator>Aliya Zeng</dc:creator>
<dc:creator>Iris Wu</dc:creator>
<dc:creator>Elena C Leon</dc:creator>
<dc:creator>Tawny Neal Qureshi</dc:creator>
<dc:creator>Christopher A Reid</dc:creator>
<dc:creator>Emily R Nettesheim</dc:creator>
<dc:creator>Emma Xu</dc:creator>
<dc:creator>Zoe Duclos</dc:creator>
<dc:creator>Tamer M A Mohamed</dc:creator>
<dc:creator>Farshad Farshidfar</dc:creator>
<dc:creator>Anthony Fejes</dc:creator>
<dc:creator>Jun Liu</dc:creator>
<dc:creator>Samantha Jones</dc:creator>
<dc:creator>Charles Feathers</dc:creator>
<dc:creator>Tae Won Chung</dc:creator>
<dc:creator>Frank Jing</dc:creator>
<dc:creator>William S Prince</dc:creator>
<dc:creator>JianMin Lin</dc:creator>
<dc:creator>Pengzhi Yu</dc:creator>
<dc:creator>Deepak Srivastava</dc:creator>
<dc:creator>Timothy Hoey</dc:creator>
<dc:creator>Kathryn N Ivey</dc:creator>
<dc:creator>Laura M Lombardi</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus</dc:title>
<dc:identifier>pmid:37602409</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.061542</dc:identifier>
</item>
<item>
<title>Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37602376/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 21. doi: 10.1161/CIRCULATIONAHA.123.065770. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >;96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98-1.83]; <i>P</i>=0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6-1.7]; <i>P</i>=0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4-1.7]; <i>P</i>=0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1-2.7]; <i>P</i>=0.02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT02100722.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37602376/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37602376</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065770>10.1161/CIRCULATIONAHA.123.065770</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37602376</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Frederik M Zimmermann</dc:creator>
<dc:creator>Victoria Y Ding</dc:creator>
<dc:creator>Nico H J Pijls</dc:creator>
<dc:creator>Zsolt Piroth</dc:creator>
<dc:creator>Albert H M van Straten</dc:creator>
<dc:creator>Laszlo Szekely</dc:creator>
<dc:creator>Giedrius Davidavicius</dc:creator>
<dc:creator>Gintaras Kalinauskas</dc:creator>
<dc:creator>Samer Mansour</dc:creator>
<dc:creator>Rajesh Kharbanda</dc:creator>
<dc:creator>Nikolaos Östlund-Papadogeorgos</dc:creator>
<dc:creator>Adel Aminian</dc:creator>
<dc:creator>Keith G Oldroyd</dc:creator>
<dc:creator>Nawwar Al-Attar</dc:creator>
<dc:creator>Nikola Jagic</dc:creator>
<dc:creator>Jan-Henk E Dambrink</dc:creator>
<dc:creator>Petr Kala</dc:creator>
<dc:creator>Oskar Angeras</dc:creator>
<dc:creator>Philip MacCarthy</dc:creator>
<dc:creator>Olaf Wendler</dc:creator>
<dc:creator>Filip Casselman</dc:creator>
<dc:creator>Nils Witt</dc:creator>
<dc:creator>Kreton Mavromatis</dc:creator>
<dc:creator>Steven E S Miner</dc:creator>
<dc:creator>Jaydeep Sarma</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Evald H Christiansen</dc:creator>
<dc:creator>Pim A L Tonino</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:creator>Hisao Otsuki</dc:creator>
<dc:creator>Yuhei Kobayashi</dc:creator>
<dc:creator>Mark A Hlatky</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>Manisha Desai</dc:creator>
<dc:creator>Y Joseph Woo</dc:creator>
<dc:creator>Alan C Yeung</dc:creator>
<dc:creator>Bernard De Bruyne</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>FAME 3 Investigators</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial</dc:title>
<dc:identifier>pmid:37602376</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065770</dc:identifier>
</item>
<item>
<title>Epilepsy and long-term risk of arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37602368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: This study revealed the higher risk of cardiac arrhythmias persists long term in people with epilepsy, especially among those using carbamazepine and valproic acid. These findings highlight the need for regular heart rhythm monitoring and management in people with epilepsy in order to reduce the risk of further cardiovascular complications.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 21:ehad523. doi: 10.1093/eurheartj/ehad523. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Previous evidence has mainly supported transient changes in cardiac function during interictal or peri-ictal phases in people with epilepsy, but the long-term risk of cardiac arrhythmias is poorly described. This study aimed to assess the long-term association of epilepsy with cardiac arrhythmias, considering the potential role of genetic predisposition and antiseizure medications (ASMs) in any associations observed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This population-based study evaluated UK Biobank data for individuals recruited between 2006 and 2010. Cox proportional hazards models and competing risk models were used to examine the association of epilepsy history with the long-term incidence risk of cardiac arrhythmias and arrhythmias subtypes. Polygenic risk scores (PRS) were calculated to investigate the effect of genetic susceptibility. The role of ASMs was also evaluated by integrating observational and drug target Mendelian randomization (MR) evidence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 329 432 individuals, including 2699 people with epilepsy. Compared with those without epilepsy, people with epilepsy experienced an increased risk of all cardiac arrhythmias [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.21-1.53], atrial fibrillation (HR 1.26, 95% CI 1.08-1.46), and other cardiac arrhythmias (HR 1.56, 95% CI 1.34-1.81). The associations were not modified by genetic predisposition as indicated by PRS. Competing and sensitivity analyses corroborated these results. Individuals with epilepsy using ASMs, especially carbamazepine and valproic acid, were at a higher risk for cardiac arrhythmias. This observation was further supported by drug target MR results (PSMR &lt; .05 and PHEIDI >; .05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: This study revealed the higher risk of cardiac arrhythmias persists long term in people with epilepsy, especially among those using carbamazepine and valproic acid. These findings highlight the need for regular heart rhythm monitoring and management in people with epilepsy in order to reduce the risk of further cardiovascular complications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37602368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37602368</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad523>10.1093/eurheartj/ehad523</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37602368</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jie Wang</dc:creator>
<dc:creator>Peiyuan Huang</dc:creator>
<dc:creator>Qingwei Yu</dc:creator>
<dc:creator>Jun Lu</dc:creator>
<dc:creator>Pinbo Liu</dc:creator>
<dc:creator>Yiping Yang</dc:creator>
<dc:creator>Zeying Feng</dc:creator>
<dc:creator>Jingjing Cai</dc:creator>
<dc:creator>Guoping Yang</dc:creator>
<dc:creator>Hong Yuan</dc:creator>
<dc:creator>Haibo Tang</dc:creator>
<dc:creator>Yao Lu</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Epilepsy and long-term risk of arrhythmias</dc:title>
<dc:identifier>pmid:37602368</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad523</dc:identifier>
</item>
<item>
<title>Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37599464/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>Obesity is a modifiable cardiovascular risk factor, but adipose tissue (AT) depots in humans are anatomically, histologically, and functionally heterogeneous. For example, visceral AT is a pro-atherogenic secretory AT depot, while subcutaneous AT represents a more classical energy storage depot. Perivascular adipose tissue (PVAT) regulates vascular biology via paracrine cross-talk signals. In this position paper, the state-of-the-art knowledge of various AT depots is reviewed providing a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 21:ehad484. doi: 10.1093/eurheartj/ehad484. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Obesity is a modifiable cardiovascular risk factor, but adipose tissue (AT) depots in humans are anatomically, histologically, and functionally heterogeneous. For example, visceral AT is a pro-atherogenic secretory AT depot, while subcutaneous AT represents a more classical energy storage depot. Perivascular adipose tissue (PVAT) regulates vascular biology via paracrine cross-talk signals. In this position paper, the state-of-the-art knowledge of various AT depots is reviewed providing a consensus definition of PVAT around the coronary arteries, as the AT surrounding the artery up to a distance from its outer wall equal to the luminal diameter of the artery. Special focus is given to the interactions between PVAT and the vascular wall that render PVAT a potential therapeutic target in cardiovascular diseases. This Clinical Consensus Statement also discusses the role of PVAT as a clinically relevant source of diagnostic and prognostic biomarkers of vascular function, which may guide precision medicine in atherosclerosis, hypertension, heart failure, and other cardiovascular diseases. In this article, its role as a 'biosensor' of vascular inflammation is highlighted with description of recent imaging technologies that visualize PVAT in clinical practice, allowing non-invasive quantification of coronary inflammation and the related residual cardiovascular inflammatory risk, guiding deployment of therapeutic interventions. Finally, the current and future clinical applicability of artificial intelligence and machine learning technologies is reviewed that integrate PVAT information into prognostic models to provide clinically meaningful information in primary and secondary prevention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37599464/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37599464</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad484>10.1093/eurheartj/ehad484</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37599464</guid>
<pubDate>Mon, 21 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Charalambos Antoniades</dc:creator>
<dc:creator>Dimitris Tousoulis</dc:creator>
<dc:creator>Marija Vavlukis</dc:creator>
<dc:creator>Ingrid Fleming</dc:creator>
<dc:creator>Dirk J Duncker</dc:creator>
<dc:creator>Etto Eringa</dc:creator>
<dc:creator>Olivia Manfrini</dc:creator>
<dc:creator>Alexios S Antonopoulos</dc:creator>
<dc:creator>Evangelos Oikonomou</dc:creator>
<dc:creator>Teresa Padró</dc:creator>
<dc:creator>Danijela Trifunovic-Zamaklar</dc:creator>
<dc:creator>Giuseppe De Luca</dc:creator>
<dc:creator>Tomasz Guzik</dc:creator>
<dc:creator>Edina Cenko</dc:creator>
<dc:creator>Ana Djordjevic-Dikic</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-08-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers</dc:title>
<dc:identifier>pmid:37599464</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad484</dc:identifier>
</item>
<item>
<title>Epigenetic memory of coronavirus infection in innate immune cells and their progenitors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37597510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>Inflammation can trigger lasting phenotypes in immune and non-immune cells. Whether and how human infections and associated inflammation can form innate immune memory in hematopoietic stem and progenitor cells (HSPC) has remained unclear. We found that circulating HSPC, enriched from peripheral blood, captured the diversity of bone marrow HSPC, enabling investigation of their epigenomic reprogramming following coronavirus disease 2019 (COVID-19). Alterations in innate immune phenotypes and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 15:S0092-8674(23)00796-1. doi: 10.1016/j.cell.2023.07.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Inflammation can trigger lasting phenotypes in immune and non-immune cells. Whether and how human infections and associated inflammation can form innate immune memory in hematopoietic stem and progenitor cells (HSPC) has remained unclear. We found that circulating HSPC, enriched from peripheral blood, captured the diversity of bone marrow HSPC, enabling investigation of their epigenomic reprogramming following coronavirus disease 2019 (COVID-19). Alterations in innate immune phenotypes and epigenetic programs of HSPC persisted for months to 1 year following severe COVID-19 and were associated with distinct transcription factor (TF) activities, altered regulation of inflammatory programs, and durable increases in myelopoiesis. HSPC epigenomic alterations were conveyed, through differentiation, to progeny innate immune cells. Early activity of IL-6 contributed to these persistent phenotypes in human COVID-19 and a mouse coronavirus infection model. Epigenetic reprogramming of HSPC may underlie altered immune function following infection and be broadly relevant, especially for millions of COVID-19 survivors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37597510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37597510</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.019>10.1016/j.cell.2023.07.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37597510</guid>
<pubDate>Sat, 19 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jin-Gyu Cheong</dc:creator>
<dc:creator>Arjun Ravishankar</dc:creator>
<dc:creator>Siddhartha Sharma</dc:creator>
<dc:creator>Christopher N Parkhurst</dc:creator>
<dc:creator>Simon A Grassmann</dc:creator>
<dc:creator>Claire K Wingert</dc:creator>
<dc:creator>Paoline Laurent</dc:creator>
<dc:creator>Sai Ma</dc:creator>
<dc:creator>Lucinda Paddock</dc:creator>
<dc:creator>Isabella C Miranda</dc:creator>
<dc:creator>Emin Onur Karakaslar</dc:creator>
<dc:creator>Djamel Nehar-Belaid</dc:creator>
<dc:creator>Asa Thibodeau</dc:creator>
<dc:creator>Michael J Bale</dc:creator>
<dc:creator>Vinay K Kartha</dc:creator>
<dc:creator>Jim K Yee</dc:creator>
<dc:creator>Minh Y Mays</dc:creator>
<dc:creator>Chenyang Jiang</dc:creator>
<dc:creator>Andrew W Daman</dc:creator>
<dc:creator>Alexia Martinez de Paz</dc:creator>
<dc:creator>Dughan Ahimovic</dc:creator>
<dc:creator>Victor Ramos</dc:creator>
<dc:creator>Alexander Lercher</dc:creator>
<dc:creator>Erik Nielsen</dc:creator>
<dc:creator>Sergio Alvarez-Mulett</dc:creator>
<dc:creator>Ling Zheng</dc:creator>
<dc:creator>Andrew Earl</dc:creator>
<dc:creator>Alisha Yallowitz</dc:creator>
<dc:creator>Lexi Robbins</dc:creator>
<dc:creator>Elyse LaFond</dc:creator>
<dc:creator>Karissa L Weidman</dc:creator>
<dc:creator>Sabrina Racine-Brzostek</dc:creator>
<dc:creator>He S Yang</dc:creator>
<dc:creator>David R Price</dc:creator>
<dc:creator>Louise Leyre</dc:creator>
<dc:creator>André F Rendeiro</dc:creator>
<dc:creator>Hiranmayi Ravichandran</dc:creator>
<dc:creator>Junbum Kim</dc:creator>
<dc:creator>Alain C Borczuk</dc:creator>
<dc:creator>Charles M Rice</dc:creator>
<dc:creator>R Brad Jones</dc:creator>
<dc:creator>Edward J Schenck</dc:creator>
<dc:creator>Robert J Kaner</dc:creator>
<dc:creator>Amy Chadburn</dc:creator>
<dc:creator>Zhen Zhao</dc:creator>
<dc:creator>Virginia Pascual</dc:creator>
<dc:creator>Olivier Elemento</dc:creator>
<dc:creator>Robert E Schwartz</dc:creator>
<dc:creator>Jason D Buenrostro</dc:creator>
<dc:creator>Rachel E Niec</dc:creator>
<dc:creator>Franck J Barrat</dc:creator>
<dc:creator>Lindsay Lief</dc:creator>
<dc:creator>Joseph C Sun</dc:creator>
<dc:creator>Duygu Ucar</dc:creator>
<dc:creator>Steven Z Josefowicz</dc:creator>
<dc:date>2023-08-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Epigenetic memory of coronavirus infection in innate immune cells and their progenitors</dc:title>
<dc:identifier>pmid:37597510</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.019</dc:identifier>
</item>
<item>
<title>Plaque morphology, inflammation, and outcome: cautious and tempered interpretation warranted</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37596979/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 19:ehad527. doi: 10.1093/eurheartj/ehad527. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37596979/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37596979</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad527>10.1093/eurheartj/ehad527</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37596979</guid>
<pubDate>Sat, 19 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2023-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Plaque morphology, inflammation, and outcome: cautious and tempered interpretation warranted</dc:title>
<dc:identifier>pmid:37596979</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad527</dc:identifier>
</item>
<item>
<title>Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595566/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>Mucosal-associated invariant T (MAIT) cells represent an abundant innate-like T cell subtype in the human liver. MAIT cells are assigned crucial roles in regulating immunity and inflammation, yet their role in liver cancer remains elusive. Here, we present a MAIT cell-centered profiling of hepatocellular carcinoma (HCC) using scRNA-seq, flow cytometry, and co-detection by indexing (CODEX) imaging of paired patient samples. These analyses highlight the heterogeneity and dysfunctionality of MAIT...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3686-3705.e32. doi: 10.1016/j.cell.2023.07.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mucosal-associated invariant T (MAIT) cells represent an abundant innate-like T cell subtype in the human liver. MAIT cells are assigned crucial roles in regulating immunity and inflammation, yet their role in liver cancer remains elusive. Here, we present a MAIT cell-centered profiling of hepatocellular carcinoma (HCC) using scRNA-seq, flow cytometry, and co-detection by indexing (CODEX) imaging of paired patient samples. These analyses highlight the heterogeneity and dysfunctionality of MAIT cells in HCC and their defective capacity to infiltrate liver tumors. Machine-learning tools were used to dissect the spatial cellular interaction network within the MAIT cell neighborhood. Co-localization in the adjacent liver and interaction between niche-occupying CSF1R<sup>+</sup>PD-L1<sup>+</sup> tumor-associated macrophages (TAMs) and MAIT cells was identified as a key regulatory element of MAIT cell dysfunction. Perturbation of this cell-cell interaction in ex vivo co-culture studies using patient samples and murine models reinvigorated MAIT cell cytotoxicity. These studies suggest that aPD-1/aPD-L1 therapies target MAIT cells in HCC patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595566/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37595566</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.026>10.1016/j.cell.2023.07.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595566</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Benjamin Ruf</dc:creator>
<dc:creator>Matthias Bruhns</dc:creator>
<dc:creator>Sepideh Babaei</dc:creator>
<dc:creator>Noemi Kedei</dc:creator>
<dc:creator>Lichun Ma</dc:creator>
<dc:creator>Mahler Revsine</dc:creator>
<dc:creator>Mohamed-Reda Benmebarek</dc:creator>
<dc:creator>Chi Ma</dc:creator>
<dc:creator>Bernd Heinrich</dc:creator>
<dc:creator>Varun Subramanyam</dc:creator>
<dc:creator>Jonathan Qi</dc:creator>
<dc:creator>Simon Wabitsch</dc:creator>
<dc:creator>Benjamin L Green</dc:creator>
<dc:creator>Kylynda C Bauer</dc:creator>
<dc:creator>Yuta Myojin</dc:creator>
<dc:creator>Layla T Greten</dc:creator>
<dc:creator>Justin D McCallen</dc:creator>
<dc:creator>Patrick Huang</dc:creator>
<dc:creator>Rajiv Trehan</dc:creator>
<dc:creator>Xin Wang</dc:creator>
<dc:creator>Amran Nur</dc:creator>
<dc:creator>Dana Qiang Murphy Soika</dc:creator>
<dc:creator>Marie Pouzolles</dc:creator>
<dc:creator>Christine N Evans</dc:creator>
<dc:creator>Raj Chari</dc:creator>
<dc:creator>David E Kleiner</dc:creator>
<dc:creator>William Telford</dc:creator>
<dc:creator>Kimia Dadkhah</dc:creator>
<dc:creator>Allison Ruchinskas</dc:creator>
<dc:creator>Merrill K Stovroff</dc:creator>
<dc:creator>Jiman Kang</dc:creator>
<dc:creator>Kesha Oza</dc:creator>
<dc:creator>Mathuros Ruchirawat</dc:creator>
<dc:creator>Alexander Kroemer</dc:creator>
<dc:creator>Xin Wei Wang</dc:creator>
<dc:creator>Manfred Claassen</dc:creator>
<dc:creator>Firouzeh Korangy</dc:creator>
<dc:creator>Tim F Greten</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin</dc:title>
<dc:identifier>pmid:37595566</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.026</dc:identifier>
</item>
<item>
<title>A conserved family of immune effectors cleaves cellular ATP upon viral infection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>During viral infection, cells can deploy immune strategies that deprive viruses of molecules essential for their replication. Here, we report a family of immune effectors in bacteria that, upon phage infection, degrade cellular adenosine triphosphate (ATP) and deoxyadenosine triphosphate (dATP) by cleaving the N-glycosidic bond between the adenine and sugar moieties. These ATP nucleosidase effectors are widely distributed within multiple bacterial defense systems, including cyclic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3619-3631.e13. doi: 10.1016/j.cell.2023.07.020.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">During viral infection, cells can deploy immune strategies that deprive viruses of molecules essential for their replication. Here, we report a family of immune effectors in bacteria that, upon phage infection, degrade cellular adenosine triphosphate (ATP) and deoxyadenosine triphosphate (dATP) by cleaving the N-glycosidic bond between the adenine and sugar moieties. These ATP nucleosidase effectors are widely distributed within multiple bacterial defense systems, including cyclic oligonucleotide-based antiviral signaling systems (CBASS), prokaryotic argonautes, and nucleotide-binding leucine-rich repeat (NLR)-like proteins, and we show that ATP and dATP degradation during infection halts phage propagation. By analyzing homologs of the immune ATP nucleosidase domain, we discover and characterize Detocs, a family of bacterial defense systems with a two-component phosphotransfer-signaling architecture. The immune ATP nucleosidase domain is also encoded within diverse eukaryotic proteins with immune-like architectures, and we show biochemically that eukaryotic homologs preserve the ATP nucleosidase activity. Our findings suggest that ATP and dATP degradation is a cell-autonomous innate immune strategy conserved across the tree of life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37595565</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.020>10.1016/j.cell.2023.07.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595565</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Francois Rousset</dc:creator>
<dc:creator>Erez Yirmiya</dc:creator>
<dc:creator>Shahar Nesher</dc:creator>
<dc:creator>Alexander Brandis</dc:creator>
<dc:creator>Tevie Mehlman</dc:creator>
<dc:creator>Maxim Itkin</dc:creator>
<dc:creator>Sergey Malitsky</dc:creator>
<dc:creator>Adi Millman</dc:creator>
<dc:creator>Sarah Melamed</dc:creator>
<dc:creator>Rotem Sorek</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A conserved family of immune effectors cleaves cellular ATP upon viral infection</dc:title>
<dc:identifier>pmid:37595565</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.020</dc:identifier>
</item>
<item>
<title>An ethical framework for human embryology with embryo models</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595564/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>A human embryo's legal definition and its entitlement to protection vary greatly worldwide. Recently, human pluripotent stem cells have been used to form in vitro models of early embryos that have challenged legal definitions and raised questions regarding their usage. In this light, we propose a refined legal definition of an embryo, suggest "tipping points" for when human embryo models could eventually be afforded similar protection to that of embryos, and then revisit basic ethical principles...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3548-3557. doi: 10.1016/j.cell.2023.07.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A human embryo's legal definition and its entitlement to protection vary greatly worldwide. Recently, human pluripotent stem cells have been used to form in vitro models of early embryos that have challenged legal definitions and raised questions regarding their usage. In this light, we propose a refined legal definition of an embryo, suggest "tipping points" for when human embryo models could eventually be afforded similar protection to that of embryos, and then revisit basic ethical principles that might help to draft a roadmap for the gradual, justified usage of embryo models in a manner that aims to maximize benefits to society.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595564/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37595564</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.028>10.1016/j.cell.2023.07.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595564</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Nicolas C Rivron</dc:creator>
<dc:creator>Alfonso Martinez Arias</dc:creator>
<dc:creator>Martin F Pera</dc:creator>
<dc:creator>Naomi Moris</dc:creator>
<dc:creator>Hafez Ismaili M'hamdi</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An ethical framework for human embryology with embryo models</dc:title>
<dc:identifier>pmid:37595564</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.028</dc:identifier>
</item>
<item>
<title>Insights and strategies for improving equity in graduate school admissions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37595563/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822203524&amp;v=2.17.9.post6+86293ac
      <description>Applying to graduate school can be particularly challenging for students from historically minoritized backgrounds due to a hidden curriculum in the graduate admissions process. To address this issue, a team of volunteer STEM trainees established the Científico Latino Graduate Student Mentorship Initiative (CL-GSMI) in 2019 to support applicants from historically minoritized backgrounds. CL-GSMI is designed to improve access to critical resources, including information, mentorship, and financial...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 17;186(17):3529-3547. doi: 10.1016/j.cell.2023.07.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Applying to graduate school can be particularly challenging for students from historically minoritized backgrounds due to a hidden curriculum in the graduate admissions process. To address this issue, a team of volunteer STEM trainees established the Científico Latino Graduate Student Mentorship Initiative (CL-GSMI) in 2019 to support applicants from historically minoritized backgrounds. CL-GSMI is designed to improve access to critical resources, including information, mentorship, and financial support, and has assisted 443 students in applying and matriculating to graduate school. Using program evaluation data from 2020 to 2021, we highlight areas in graduate school admissions that can be improved to promote equity and inclusion.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37595563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822203524&v=2.17.9.post6+86293ac">37595563</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.029>10.1016/j.cell.2023.07.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37595563</guid>
<pubDate>Fri, 18 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Melissa Andrea Cadena</dc:creator>
<dc:creator>Cathy Amaya</dc:creator>
<dc:creator>Daisy Duan</dc:creator>
<dc:creator>Carlos Alberto Rico</dc:creator>
<dc:creator>Leonor García-Bayona</dc:creator>
<dc:creator>Aníbal Tornes Blanco</dc:creator>
<dc:creator>Yessica Santana Agreda</dc:creator>
<dc:creator>Gonzalo Javier Villegas Rodríguez</dc:creator>
<dc:creator>Alexis Ceja</dc:creator>
<dc:creator>Vianna G Martinez</dc:creator>
<dc:creator>Olivia V Goldman</dc:creator>
<dc:creator>Robert W Fernandez</dc:creator>
<dc:date>2023-08-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Insights and strategies for improving equity in graduate school admissions</dc:title>
<dc:identifier>pmid:37595563</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.029</dc:identifier>
</item>





























</channel>
</rss>